Mohit Khera1, Ganesh Adaikan2, Jacques Buvat3, Serge Carrier4, Amr El-Meliegy5, Kostas Hatzimouratidis6, Andrew McCullough7, Abraham Morgentaler8, Luiz Otavio Torres9, Andrea Salonia10. 1. Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA. Electronic address: mkhera@bcm.edu. 2. Section of Sexual Medicine, Obstetrics and Gynaecology, National University Hospital, National University of Singapore, Singapore. 3. CETPARP (Centre d'études et de traitement de la pathologie de l'appareil reproducteur), Lille, France. 4. Department of Urology, McGill University, Montreal, QC, Canada. 5. Department of Andrology, Dr Soliman Fakeeh Hospital, Jeddah, Saudi Arabia. 6. Second Department of Urology, Aristotle University of Thessaloniki, Pefka Thessaloniki, Greece. 7. Department of Urology, Albany Medical Center, Albany, NY, USA. 8. Men's Health Boston and Harvard Medical School, Boston, MA, USA. 9. Centro Universitário UniBH, Belo Horizonte, Minas Gerais, Brazil. 10. Università Vita-Salute San Raffaele, Milan, Italy.
Abstract
INTRODUCTION: Testosterone deficiency (TD), also known as hypogonadism, is a condition affecting a substantial proportion of men as they age. The diagnosis and management of TD can be challenging and clinicians should be aware of the current literature on this condition. AIM: To review the available literature concerning the diagnosis and management of TD and to provide clinically relevant recommendations from the Fourth International Consultation for Sexual Medicine (ICSM) meeting. METHODS: A literature search was performed using the PubMed database for English-language original and review articles published or e-published up to January 2016. MAIN OUTCOME MEASURES: Levels of evidence (LoEs) and grades of recommendations are provided based on a thorough analysis of the literature and committee consensus. RESULTS: Recommendations were given for 12 categories of TD: definition, clinical diagnosis, routine measurement, screening questionnaires, laboratory diagnosis, threshold levels for the biochemical diagnosis of TD, prostate cancer, cardiovascular disease, fertility, testosterone (T) formulations, alternatives to T therapy, and adverse events and monitoring. A total of 42 recommendations were made: of these, 16 were unchanged from the Third ICSM and 26 new recommendations were made during this Fourth ICSM. Most of these recommendations were supported by LoEs 2 and 3. Several key new recommendations include the following: (i) the clinical manifestations of TD occur as a result of decreased serum androgen concentrations or activity, regardless of whether there is an identified underlying etiology [LoE = 1, Grade = A]; (ii) symptomatic men with total T levels lower than 12 nmol/L or 350 ng/dL should be treated with T therapy [LoE = 1, Grade = C]; (iii) a trial of T therapy in symptomatic men with total T levels higher than 12 nmol/L or 350 ng/dL can be considered based on clinical presentation [LoE = 3, Grade = C]; (iv) there is no compelling evidence that T treatment increases the risk of developing prostate cancer or that its use is associated with prostate cancer progression [LoE = 1, Grade = C]; and (v) the weight of evidence indicates that T therapy is not associated with increased cardiovascular risk [LoE = 2, Grade = B]. CONCLUSION: TD is an important condition that can profoundly affect the sexual health of men. We provide guidance regarding its diagnosis and management. Men with TD who receive treatment often experience resolution or improvement in their sexual symptoms and non-sexual health benefits. Copyright Â
INTRODUCTION:Testosterone deficiency (TD), also known as hypogonadism, is a condition affecting a substantial proportion of men as they age. The diagnosis and management of TD can be challenging and clinicians should be aware of the current literature on this condition. AIM: To review the available literature concerning the diagnosis and management of TD and to provide clinically relevant recommendations from the Fourth International Consultation for Sexual Medicine (ICSM) meeting. METHODS: A literature search was performed using the PubMed database for English-language original and review articles published or e-published up to January 2016. MAIN OUTCOME MEASURES: Levels of evidence (LoEs) and grades of recommendations are provided based on a thorough analysis of the literature and committee consensus. RESULTS: Recommendations were given for 12 categories of TD: definition, clinical diagnosis, routine measurement, screening questionnaires, laboratory diagnosis, threshold levels for the biochemical diagnosis of TD, prostate cancer, cardiovascular disease, fertility, testosterone (T) formulations, alternatives to T therapy, and adverse events and monitoring. A total of 42 recommendations were made: of these, 16 were unchanged from the Third ICSM and 26 new recommendations were made during this Fourth ICSM. Most of these recommendations were supported by LoEs 2 and 3. Several key new recommendations include the following: (i) the clinical manifestations of TD occur as a result of decreased serum androgen concentrations or activity, regardless of whether there is an identified underlying etiology [LoE = 1, Grade = A]; (ii) symptomatic men with total T levels lower than 12 nmol/L or 350 ng/dL should be treated with T therapy [LoE = 1, Grade = C]; (iii) a trial of T therapy in symptomatic men with total T levels higher than 12 nmol/L or 350 ng/dL can be considered based on clinical presentation [LoE = 3, Grade = C]; (iv) there is no compelling evidence that T treatment increases the risk of developing prostate cancer or that its use is associated with prostate cancer progression [LoE = 1, Grade = C]; and (v) the weight of evidence indicates that T therapy is not associated with increased cardiovascular risk [LoE = 2, Grade = B]. CONCLUSION: TD is an important condition that can profoundly affect the sexual health of men. We provide guidance regarding its diagnosis and management. Men with TD who receive treatment often experience resolution or improvement in their sexual symptoms and non-sexual health benefits. Copyright Â
Authors: R Matthew Coward; Christy Stetter; Allen Kunselman; J C Trussell; Mark C Lindgren; Ruben R Alvero; Peter Casson; Gregory M Christman; Christos Coutifaris; Michael P Diamond; Karl R Hansen; Stephen A Krawetz; Richard S Legro; Randal D Robinson; James F Smith; Anne Z Steiner; Robert A Wild; Heping Zhang; Nanette Santoro Journal: J Urol Date: 2019-07-08 Impact factor: 7.450
Authors: Hui Zhou; Yuesong Wang; Matthew Gatcombe; Jacob Farris; Julianne C Botelho; Samuel P Caudill; Hubert W Vesper Journal: Anal Bioanal Chem Date: 2017-08-11 Impact factor: 4.142
Authors: Andrea Salonia; Giulia Rastrelli; Geoffrey Hackett; Stephanie B Seminara; Ilpo T Huhtaniemi; Rodolfo A Rey; Wayne J G Hellstrom; Mark R Palmert; Giovanni Corona; Gert R Dohle; Mohit Khera; Yee-Ming Chan; Mario Maggi Journal: Nat Rev Dis Primers Date: 2019-05-30 Impact factor: 52.329
Authors: Kathryn E Flynn; Dane Whicker; Li Lin; Rachel Cusatis; Alan Nyitray; Kevin P Weinfurt Journal: J Gen Intern Med Date: 2019-08-26 Impact factor: 5.128
Authors: D S Lopez; W Wulaningsih; K K Tsilidis; J Baillargeon; S B Williams; R Urban; S Rohrmann Journal: Hormones (Athens) Date: 2020-02-19 Impact factor: 2.885
Authors: David S Lopez; Lydia Liu; Stephanie A Smith-Warner; Konstantinos K Tsilidis; Carrie Daniel; Jacques Baillargeon; Sabine Rohrmann; Elizabeth A Platz; Edward Giovannucci Journal: Hormones (Athens) Date: 2022-01-11 Impact factor: 3.419
Authors: Rob F Walker; Neil A Zakai; Richard F MacLehose; Logan T Cowan; Terrence J Adam; Alvaro Alonso; Pamela L Lutsey Journal: JAMA Intern Med Date: 2020-02-01 Impact factor: 21.873